New technique preserves major nerves, blood vessels, and other critical structures in a hard-to-access area. In a ...

The COAT trial was a multilabel phase 4 study that evaluated the efficacy of a 0.09% cyclosporine solution administered twice daily to patients over a 28-day period. Assessments occurred at ...

CHICAGO — In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous mosunetuzumab in patients with previously untreated, high-tumor ...

Session ID: 2025-07-02:4d5fa2e1d3ea57191fac9102 Player Element ID: V61ce242e_558c_447e_9107_acb9fd2d6e1d_6374466286112 ...

Incyte Lymphoma Treatment Gets FDA Approval Published: June 18, 2025, 4:12 p.m. ET Share Resize ...

Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new ...

The phase 2 MorningSun trial (NCT05207670) included 102 patients with previously untreated follicular lymphoma. 2 The median patient age was 64.5 years, 53.9% of patients had stage IV disease, and ...

No writing assistance was utilized in the production of this manuscipt. Cite this: Diagnosis and Management of Malignant Tumors of the Eyelid, Conjunctiva, and Orbit - Medscape - Jan 01, 2008.

Data presented from the marginal zone lymphoma (MZL) cohort of the TRANSCEND FL trial (NCT04245839) demonstrated high rates of durable responses with the chimeric antigen receptor (CAR) T-cell therapy ...

Purpose To report the ocular characteristics and the presence of viral RNA of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in conjunctival swab specimens in a patient with confirmed ...

Case Presentation A 19-year-old Caucasian female was referred to the Ocular Oncology Service, Department of Ophthalmology, Poznań, Poland in April 2009 with a suspicion of conjunctival lymphoma.